FDA Approves Oral Powder for Sickle Cell Disease

JULY 07, 2017
Kevin Kunzmann

The US Food and Drug Administration (FDA) has approved L-glutamine oral powder (Endari) for the treatment of sickle cell disease (SCD) complications in adult and pediatric patients aged 5 years or older.

The treatment is the first approved by the FDA for pediatric SCD patients and the first new adult SCD treatment in nearly 2 decades.

The powder, produced by Emmaus Medical, Inc., was approved following a randomized, double-blind, placebo-controlled, multi-center clinical trial involving 230 sickle cell anemia or sickle beta-thalssemia patients. The patients, who had to have had at least 2 painful crisus within 12 months fo enrollment, were randomized to receive either L-glutamine or placebo for 48 weeks followed by three weeks of drug tapering.

Over the testing perioud, L-glutamine patients reported a median of 3 sickle cell crises, compated to the placebo patients' median of 4 crises. A crisis was defined as a disease-related medical visit for pain, treated with parenteral narcotic or ketorolac. These crises included chest syndrome, priapism, and splenic sequestration.

L-glutamine patients also reported fewer hospitalizations from sickle cell pain, fewer cumulative hospital days, and a lower acute chest syndrome incidence.

Patients reported common adverse effects such as constipation, nausea, headaches, abdominal pain, cough, and more at least 10% while taking L-glutamine versus placebo.

The recommended dose of L-glutamine is 10-30 grams twice per day, taken orally, mixed in with either drink or food.

A press release regarding the approval was made available.

Related Coverage

Endo International Pulls Opioid Treatment from Market
FDA Approves Seizure Device for Young Children
Abatacept Wins Its Third FDA Indication



Copyright© MD Magazine 2006-2017 Intellisphere, LLC. All Rights Reserved.